Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM
8-K
CURRENT
REPORT
Pursuant
to section 13 or 15 (d) of the
Securities
Exchange Act of 1934
Date
of
Report (Date of earliest event reported): November 14, 2006
BODISEN
BIOTECH, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-32616
|
98-0381367
|
(State
or other Jurisdiction of Identification Incorporation)
|
(Commission
File Number)
|
(IRS
Employer No.)
|
North
Part of Xinquia Road, Yang Ling Agricultural High-Tech
People's
Republic of China 712100
(Address
of Principal Executive Offices)
86-29-87074957
(Registrant’s
Telephone Number, including Area Code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
2.02. Results of Operations and Financial Condition.
On
November 14, 2006, Bodisen Biotech, Inc. (the “Company”) issued a press release
announcing the Company’s financial results for the quarter ended September 30,
2006. The press release is attached as Exhibit 99.1 to this Form
8-K.
Item
8.01. Other Events.
Also,
in
the same November 14, 2006 press release, the Company deemed it of importance
to
shareholders to convey information about the Company’s press release dated
November 12, 2006 regarding the letter it received from the Staff of the
American Stock Exchange. Specifically, this information is in the paragraph
of
the press release under “Amex Letter Clarification” attached as Exhibit 99.1 to
this Form 8-K.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
Description
99.1 Press
release dated November 14, 2006.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
|
|
|
BODISEN
BIOTECH,
INC. |
|
|
|
Date: November
17, 2006 |
By: |
/s/ Qiong
Wang |
|
Qiong
Wang |
|
Chief
Executive Officer |